ABBOTT LABORATORIES quarterly report, Q1 FY2023

完整文档

Abbott Laboratories 10-Q Summary

Business Context and Reporting Period

Abbott Laboratories filed an unaudited Form 10-Q for the quarter ended March 31, 2023. The company operates through four reportable segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Medical Devices.

Financial Performance and Key Metrics

  • Net sales: $9.747 billion, down 18.1% from $11.895 billion in the prior-year quarter. Sales excluding foreign exchange declined 14.8%.
  • Net earnings: $1.318 billion, compared with $2.447 billion.
  • Diluted earnings per share: $0.75, compared with $1.37.
  • Operating earnings: $1.509 billion, compared with $2.912 billion.
  • Gross profit margin: 50.5%, compared with 53.8%.
  • Operating margin: Approximately 15.5%, compared with approximately 24.5%.
  • Net margin: Approximately 13.5%, compared with approximately 20.6%.
  • Operating cash flow: $1.143 billion, down from $2.065 billion.
  • Capital expenditures: $380 million, compared with $321 million.
  • Cash and cash equivalents: $9.161 billion at March 31, 2023, compared with $9.882 billion at December 31, 2022.
  • Total debt: Approximately $16.9 billion, consisting of $2.285 billion of current debt and $14.615 billion of long-term debt.
  • Liquidity: Working capital was $9.8 billion. Abbott reported $5.0 billion of available credit lines expiring in 2025 and investment-grade debt ratings of AA- from S&P and A1 from Moody’s.
  • Shareholder returns: Abbott repurchased approximately 3.0 million shares for $300 million and declared a quarterly dividend of $0.51 per share, up 8.5% year over year.

Material Changes Versus the Prior Comparable Period

  • COVID-19 testing normalization: COVID-19 testing-related sales fell to approximately $730 million from $3.3 billion. Excluding these sales, total revenue increased 4.9%, or 9.4% excluding both COVID-19 testing sales and foreign exchange.
  • Diagnostics: Sales declined 48.9% overall and 47.1% excluding foreign exchange, primarily because of lower rapid and molecular COVID-19 testing demand. Segment operating earnings fell to $651 million from $2.564 billion.
  • Medical Devices: Sales increased 8.5% overall and 12.4% excluding foreign exchange. Growth was led by Diabetes Care, Structural Heart, Heart Failure, and Neuromodulation. FreeStyle Libre sales increased 25.4% excluding foreign exchange to approximately $1.2 billion.
  • Nutritional Products: Sales increased 3.8% overall and 7.7% excluding foreign exchange, benefiting from the nonrecurrence of the prior-year infant-formula recall impact.
  • Established Pharmaceutical Products: Sales increased 3.7% overall and 11.1% excluding foreign exchange.
  • Profitability: Gross margin declined because of lower COVID-19 test sales, foreign exchange, and higher manufacturing input costs, partly offset by margin improvement initiatives and the absence of 2022 recall costs.
  • Cash generation: Operating cash flow decreased by $922 million, primarily because of lower operating earnings, partly offset by improved trade-receivable collections and lower cash taxes.

Guidance, Outlook, Risks, Contingencies, and Unusual Items

  • The filing does not provide a clear quantitative full-year earnings or revenue guidance figure.
  • Management stated that future COVID-19 testing demand is unpredictable and that the extent of its effect on Abbott’s business and results remains uncertain.
  • Abbott faces competition, pricing pressure, rebates, foreign-exchange exposure, government regulation, healthcare reimbursement changes, supply and manufacturing cost risks, and technological and product-development risks.
  • Abbott recorded approximately $17 million of restructuring charges in the quarter; the related accrued balance was $184 million at March 31, 2023.
  • Legal and environmental proceedings had an estimated possible loss range of approximately $25 million to $35 million, with an accrued balance of approximately $30 million. Management does not expect the ultimate disposition to materially adversely affect the company.
  • Abbott expects recorded gross unrecognized tax benefits to decrease by approximately $75 million to $80 million over the next twelve months as tax matters are resolved.
  • On April 27, 2023, after quarter-end, Abbott completed the approximately $850 million cash acquisition of Cardiovascular Systems, Inc., which provides atherectomy technology for peripheral and coronary artery disease.
  • Remaining performance obligations were approximately $4.1 billion in Diagnostics and $450 million in Medical Devices; Abbott expects to recognize approximately 60% over the next 24 months.

Important Facts for Investors to Verify

  • Whether the decline in COVID-19 testing revenue is offset by sustainable growth in Medical Devices, Nutritionals, and Established Pharmaceuticals.
  • The durability of FreeStyle Libre growth and the contribution from recently approved Medical Devices products.
  • The effect of foreign exchange, inflationary manufacturing costs, and margin-improvement initiatives on gross margin.
  • Updated full-year guidance, if subsequently provided, and the post-acquisition financial impact of Cardiovascular Systems, Inc.
  • Future operating cash flow after pension contributions, capital expenditures, dividends, share repurchases, and acquisition spending.
  • Debt maturities, interest-rate exposure, and the remaining $2.134 billion authorized under the share-repurchase program.
  • Developments in regulatory, litigation, environmental, tax, product-recall, and healthcare-reimbursement matters.